Lightkey and Ateknea’s collaboration comes to a successful close

/in /by

Lightkey, which was approved for Phase 2 SME Instrument funding by the European Commission in June 2016, is a technological solution designed for hotels, resorts, and offices that allows users to access their rooms with a specifically encoded LED light, and without the need for any hotel or office personnel.

Created by Lightbee, the Lightkey system is one of the first solutions that allows secure and scalable access without any of the drawbacks of the currently available mobile access solutions. Like all the best innovations, it is simple yet brilliant. Users access their VLC (Visible Light Communication) which they are sent via a mobile app. Once activated, each user’s particular LED will allow them to securely enter their rooms.

Here at Ateknea we are proud of our work to develop this technology. With the SME Instrument funding our engineers completed a variety of tasks to make this project possible. They developed:

  • An Electronic Door Lock module that permits the reception of the VLC and allow users to open their doors
  • A standalone device to send master Lightkeys
  • A mobile app (for Android and iOS) that sends the Lightkeys to the module
  • A security concept implemented in the server to manage the Lightkeys of each user and which is connected to the mobile app and the door lock.

SME Instrument funded project

Research and Innovation engineers

 

It’s a perfect solution to a complex logistical problem: increasing security, ease-of-use, and reducing costs.

We look forward to seeing what is next for Lightbee and Lightkey!

 

New Born Solutions & Ateknea: EU funding success!

/in /by

New Born Solutions and Ateknea Solutions work together to democratize healthcare in Europe, with EU funding.

Great news from Brussels! We are happy to announce that New Born Solutions, a Barcelona-based startup dedicated to saving lives and democratizing healthcare via cost-effective technology that detects superficial body fluid infections without needles, has been approved for SME Instrument Phase 1 EU funding.

With the help of Ateknea’s H2020 expertise, New Born Solutions’ latest development, Neosonics, the first non-invasive screening device designed to early detection and monitoring infant meningitis, has received €50,000 in EU funding after the European Commission gave their technology the go-ahead in late April.

The Neosonics solution is innovative, simple, and revolutionary.  

There are an estimated 165 million infants at risk of meningitis each year.

Where current practice dictates that a white blood cell count be taken from a child’s spinal fluid through a lumbar puncture (which immediately triggers the need for more medication irrespective of the diagnostic results), Neosonics uses high-resolution ultrasound to non-invasively count the white blood cell in the cerebrospinal fluid below the infant’s fontanel, the region of the head where the bones are not yet closed.

It means an early diagnosis can be quickly made in a cost-effective and non-invasive way, decreasing current complications to rule out the disease in industrialized countries and infant mortality rates, especially in developing countries. By enabling early and non-invasive detection, it could vastly reduce the amount of patients with life-long disabilities and provide quantitative and reliable data for monitoring patients’ treatment response.

We at Ateknea are excited to continue working with New Born Solutions, and to see Neosonics through to the market.